Editas Medicine Announces Nomination of EDIT-401 as Lead In Vivo Development Candidate for LDL-C Reduction, Aiming for Human Data by 2026
I'm PortAI, I can summarize articles.
Editas Medicine Inc. has nominated EDIT-401 as its lead in vivo development candidate for reducing LDL cholesterol levels. In non-human primate studies, a single dose of EDIT-401 resulted in about a 90% reduction in mean LDL-C levels. The company aims to present human proof-of-concept data by the end of 2026 and has secured operational funding until Q2 2027. A webinar on EDIT-401 is also scheduled.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments